FDA drug class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitors list
Every FDA-approved prescription drug the FDA NDC directory tags with the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
The FDA NDC directory lists 5 single-ingredient drugs in this class: adefovir dipivoxil, entecavir, lamivudine, tenofovir alafenamide, tenofovir disoproxil. Another 17 combination products include one of them.
Run it in Rivvi
Map your top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitors (22)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Adefovir dipivoxil | None listed | Single ingredient | 2 | Not controlled |
| Entecavir | Baraclude | Single ingredient | 31 | Not controlled |
| Lamivudine | Epivir | Single ingredient | 29 | Not controlled |
| Tenofovir alafenamide | Vemlidy | Single ingredient | 1 | Not controlled |
| Tenofovir disoproxil | Viread | Single ingredient | 25 | Not controlled |
| Abacavir and lamivudine | None listed | Combination | 6 | Not controlled |
| Abacavir, dolutegravir and lamivudine | Triumeq | Combination | 1 | Not controlled |
| Abacavir, lamivudine and zidovudine | None listed | Combination | 1 | Not controlled |
| Bictegravir, emtricitabine and tenofovir alafenamide | Biktarvy | Combination | 4 | Not controlled |
| Darunavir, cobicistat, emtricitabine and tenofovir alafenamide | Symtuza | Combination | 1 | Not controlled |
| Dolutegravir and lamivudine | Dovato | Combination | 1 | Not controlled |
| Doravirine, lamivudine and tenofovir disoproxil | Delstrigo | Combination | 1 | Not controlled |
| Efavirenz, emtricitabine and tenofovir disoproxil | None listed | Combination | 7 | Not controlled |
| Efavirenz, lamivudine and tenofovir disoproxil | Symfi | Combination | 3 | Not controlled |
| Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide | Genvoya | Combination | 1 | Not controlled |
| Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil | Stribild | Combination | 1 | Not controlled |
| Emtricitabine and tenofovir alafenamide | Descovy | Combination | 2 | Not controlled |
| Emtricitabine and tenofovir disoproxil | Truvada | Combination | 49 | Not controlled |
| Emtricitabine, rilpivirine and tenofovir alafenamide | Odefsey | Combination | 1 | Not controlled |
| Emtricitabine, rilpivirine and tenofovir disoproxil | Complera | Combination | 3 | Not controlled |
| Lamivudine and tenofovir disoproxil | Cimduo | Combination | 1 | Not controlled |
| Lamivudine and zidovudine | Combivir | Combination | 10 | Not controlled |
FDA established pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC].
Questions
What drugs are Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitors?
The FDA NDC directory lists 5 single-ingredient drugs in this class: adefovir dipivoxil, entecavir, lamivudine, tenofovir alafenamide, tenofovir disoproxil. Another 17 combination products include one of them.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.
Related
- Adefovir dipivoxilFDA label
- EntecavirBaraclude
- LamivudineEpivir
- Tenofovir alafenamideVemlidy
- Tenofovir disoproxilViread
- Abacavir and lamivudineFDA label
- Abacavir, dolutegravir and lamivudineTriumeq
- Bictegravir, emtricitabine and tenofovir alafenamideBiktarvy
- All drug classesFDA EPC
- Controlled substances by scheduleDEA list
- Generic drug lookupFDA Orange Book
- NDC lookupFDA NDC directory
- Medicare Part D drug coverageBy plan and state